CureVac to drop COVID-19 vaccine candidate, focus on next-gen shot

Published by

BERLIN (Reuters) -CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA vaccine technology instead, the Germany-based biotechnology company said on Tuesday. The company’s shares plunged almost 14% in afternoon trading, hitting their lowest since listing last August. The company said it will drop its application to the European Medicines Agency for regulatory approval of its first-generation vaccine candidate CVnCoV after late-stage trials delivered disappointing results with 47% efficacy in June. There would …

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *